Myasthenia Gravis Awareness Month 2026: Symptoms and trials

For people living with myasthenia gravis, the day arrives in pieces. A patient can pour coffee at nine in the morning without thinking about it and find themselves struggling to chew dinner at six in the evening. The eyelid that lifted normally at the start of the day might drift downward by mid-afternoon. Speech that was clear in the morning can slur after an hour of conversation. The defining feature of myasthenia gravis is not that muscles are weak, but that they get weaker with use and recover with rest. This pattern, more than any single symptom, is what tells a neurologist that an autoimmune disorder of the connection between nerve and muscle is the likely cause. Each June, Myasthenia Gravis Awareness Month draws attention to a rare condition that is often misread for years before it is named, and to the myasthenia gravis clinical trials working to change diagnosis and care for the roughly 70,000 Americans living with it.

What Myasthenia Gravis Awareness Month is about

Myasthenia Gravis Awareness Month is observed each June in the United States and recognized internationally. The observance is anchored by the US patient advocacy foundation for myasthenia gravis, headquartered in Massachusetts, which has worked for decades to support patients, fund research, and connect people living with the condition. The month draws on a recurring framing that asks patients, families, healthcare providers, and supporters to turn awareness into action by sharing stories, contacting elected officials, and supporting clinical research efforts.

The month exists because myasthenia gravis sits in a category of rare autoimmune disease that the general public, and many primary-care clinicians, encounter rarely enough that early symptoms are often dismissed or attributed to other causes. Awareness efforts in June focus on what myasthenia gravis looks like, what diagnosis takes, what current care can offer, and how research is expanding what is possible.

For a wider view of how research attention can change the pace of progress for less common diseases, Hope in Research: How Clinical Trials Are Transforming Rare Disease Treatment describes how visibility for an under-recognized condition can move research forward.

The symptoms and the disease

Myasthenia gravis is an autoimmune disease, which means the immune system mistakenly attacks the body's own tissue. In myasthenia gravis, the target is the neuromuscular junction, the small but critical gap where a nerve sends a chemical signal to a muscle telling it to contract. The chemical messenger is called acetylcholine. The muscle receptors that catch the signal are called acetylcholine receptors. In most patients with myasthenia gravis, the immune system makes antibodies (the proteins the immune system makes to fight invaders) that attach to these receptors and block the signal from getting through. A smaller share of patients have antibodies against a different protein at the same junction, called muscle-specific kinase (often shortened to MuSK). A smaller group still has no detectable antibodies at all, which is called seronegative myasthenia gravis.

The symptoms reflect this signal failure. The first sign for most patients is in the eyes: a drooping eyelid on one side, or double vision that comes and goes. From there, the disease can extend to facial muscles, causing slurred speech, difficulty chewing, or a changed smile; to neck and limb muscles, making it hard to hold the head up or climb stairs; and in the more serious form, to the muscles that control breathing. Roughly a third of patients have ocular myasthenia gravis, where the disease stays confined to the eye muscles. The rest progress to generalized myasthenia gravis, often shortened to gMG, where multiple muscle groups are involved.

For a plain-language overview of how clinical trials are designed and what they are for, Clinical Trials Explained: Simple Guide for Beginners covers the basics that the rest of this article builds on.

How myasthenia gravis is diagnosed

The diagnostic story for myasthenia gravis is often a long one. Symptoms come and go. A drooping eyelid in the evening that is gone by morning, slurred speech only when tired, double vision after reading for an hour, and weakness in the arms after pushing a vacuum cleaner are not the kinds of complaints that immediately suggest a neuromuscular junction disorder. Many patients see several specialists, including ophthalmologists, ear-nose-and-throat doctors, and primary care physicians, before a neurologist runs the right tests.

A confirmed diagnosis usually combines several pieces. Blood antibody tests look for acetylcholine receptor antibodies, which are present in about 85 percent of patients, and for MuSK antibodies, present in about 6 percent. Electrophysiology tests, including repetitive nerve stimulation and single-fiber electromyography, measure how the signal between nerve and muscle weakens with repeated use. Imaging of the chest checks the thymus gland, a small organ behind the breastbone that is often involved in the autoimmune process and that can be surgically removed in some patients as part of long-term care.

Because the diagnostic picture has many moving parts, and because seronegative myasthenia gravis has no antibody fingerprint, eligibility for a clinical trial often hinges on which form of the disease a patient has and which antibodies are or are not present. Eligibility Explained: Why Not Everyone Qualifies for a Trial walks through the reasoning behind those decisions.

The science: how care has expanded

For decades, the standard approach to myasthenia gravis care was layered: a daily medication that boosts the chemical signal at the neuromuscular junction to ease symptoms, combined with broader immune-suppressing medications to slow the underlying autoimmune process, with intravenous infusions or blood-plasma exchange (a procedure that filters antibodies out of the bloodstream) used during severe flares and crises, and in some patients, surgical removal of the thymus gland.

The last five years have changed that picture significantly. A new class of targeted biologic and antibody-based therapies has been approved for generalized myasthenia gravis, designed to act on specific pieces of the immune system that drive the disease rather than suppressing the immune system broadly. Some of these therapies block a piece of the immune system called the complement cascade, which contributes to the destruction of acetylcholine receptors. Others reduce the level of circulating antibodies by interfering with how the immune system recycles them. These approaches give patients and clinicians more options for patients who have not done well on older medications, although the long-term picture for the newer therapies is still being established through ongoing research.

For a wider perspective on how research moves from study to standard of care, How Clinical Trials Advance Medicine and Change Lives walks through that journey.

Clinical trials in myasthenia gravis today

Based on a search of public trial registries in June 2026, roughly 48 myasthenia gravis clinical trials are actively recruiting participants in the United States, of which about 24 are in Phase 2 or Phase 3 (the stages that test how well an approach works rather than just whether it is safe to give). Globally, the count is about 96 trials. For comparison, the broader field of recruiting neuromuscular disease studies in the United States runs to roughly 626 trials, placing myasthenia gravis at around one in every thirteen currently recruiting US neuromuscular trials. That share is meaningful for a disease as rare as myasthenia gravis, and it reflects the recent surge of interest in targeted autoimmune therapies. These counts shift as trials open and close, so the exact numbers will look different a few months from now.

The currently recruiting myasthenia gravis trials fall into a few broad categories. Some are testing new biologic therapies that target specific parts of the immune system, including patients with antibody-positive disease and patients with seronegative myasthenia gravis. Some are comparing how well existing therapies work when used at different stages of the disease, such as earlier in the course rather than after other approaches have not worked. Some are studying patients with the rare and dangerous form, myasthenic crisis (a medical emergency in which the breathing muscles are affected to the point that intensive care is needed). And some are observational, following large groups of patients over years to learn what predicts long-term response, what factors trigger relapses, and how the disease evolves.

A few concerns come up often when people start thinking about whether a trial could be right for them. One concern is that joining a study means stopping current myasthenia gravis medications. In most modern trials, the design is built around standard of care, not against it; new approaches are usually tested in addition to existing medications, not by replacing them. Another concern is that clinical trials are only for advanced or refractory cases. In myasthenia gravis, research now includes patients across the spectrum, including newly diagnosed patients and patients with stable disease who are looking for newer options. A third concern is uncertainty about side effects. Every trial follows a written plan, called a protocol (the document that defines how a study is run), and every participant goes through a careful consent conversation with the research team before agreeing to take part, including a review of the specific risks to watch for.

DecenTrialz helps people in the United States find clinical trials that may fit their situation. After someone shares basic information about themselves and the conditions they are interested in, the platform may identify trial options that appear to match their profile. A registered nurse then completes an initial pre-screening review before the person is referred to the research site running the study. The research site and study team handle the walk-through of study details, the final eligibility check, the consent conversation, and enrollment, since they are the ones responsible for the participant's care during the trial. You can start a search at decentrialz.com.

For a step-by-step look at how the path from interest to enrollment usually unfolds, How to Find and Enroll in a Clinical Trial: A Step-by-Step Guide walks through what to expect.

What June asks of everyone touched by myasthenia gravis

For patients and the people who love them, Myasthenia Gravis Awareness Month is an invitation to put words to symptoms that may have been quietly present for months or years. The fluctuating-weakness pattern, the eyelid that droops by evening, the double vision after reading, the slurred speech that comes back after a rest, is the kind of detail neurologists need to make a confident diagnosis. The earlier the conversation starts, the earlier care can begin.

For doctors and the broader clinical research community, the month is a reminder that myasthenia gravis sits in a category of rare autoimmune disease where research participation has an outsized impact. With roughly 70,000 Americans diagnosed, each enrolled patient moves the field forward in a way that would be invisible in a more common disease.

And for anyone exploring whether a current myasthenia gravis study fits their situation, June is a good time to look at what is recruiting. You can begin a search at DecenTrialz to see what is currently available.